CAPTURE your learning


Our resources are free to access. Log in and record your professional development using our CAPTURE function (at the bottom of each article).

At He Ako Hiringa our mission is to contribute to eliminating inequitable access to funded medicines.

Our latest content

Looking for up-to-date information on gout? You can find it here!

We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.

 

Contributor
He Ako Hiringa
18 October 2021
45 minutes to Delve

Following on from presentations in February, this new resource covers discussions from webinars held in August 2021.

The content has been edited, and reviewed by Waikato DHB endocrinologist/diabetologist Dr Ryan Paul.

We recommend using Google Chrome when accessing this resource. You may experience technical difficulties on other internet browsers.

Contributor
Dr Ryan Paul
13 October 2021
17 minutes to Listen

Introducing Legendary Conversations, our podcast series that explores aspects of primary care in Aotearoa New Zealand. In episode one (part 1), we talk with Professor Keith Petrie about the psychological effects of taking medicines, and what primary healthcare professionals need to know. 

Contributor
Professor Keith Petrie
11 October 2021
21 minutes to Read

Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and with drug-related morbidity and mortality. As such, it needs to be addressed holistically as part of the psychosocial medical model.

30 September 2021

Biological medicines have markedly changed prognoses for many conditions such as cancers, diabetes and autoimmune diseases.  

As biologics’ patents expire, biosimilars – highly similar versions of approved biologic brands – will be competitively marketed. This will lead to cost savings, increased access and treatment options, and improved patient outcomes.2

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
27 September 2021
8 minutes to Read

Patients can no longer be started on funded selegiline. Patients who were on selegiline prior to 1 August 2021 will need their prescriptions endorsed to receive subsidised supplies. An alternative MAO-B inhibitor, rasagiline, may be a suitable agent for new patients or those transitioning from selegiline.

This resource provides a timeline for the changes and information about transitioning patients from selegiline. Advice on prescribing rasagiline is also included.

Contributor
He Ako Hiringa
14 September 2021

Thirsty for knowledge?

Subscribe to our newsletter to remain up to date with all our content and new features.